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[EBioMedicine 2 (8), August 2015, 868–873]Mamoudou Maigaa,b,1, Bintou Ahmadou Ahidjoa,c, Mariama C. Maigaa,c, Laurene Cheunga,c, Shaaretha Pellya,c,
Shichun Luna, Flabou Bougoudogob, William R. Bishaia,c,⁎
a Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA
b Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali
c Howard Hughes Medical Institute, Chevy Chase, MD, USAOnpage 867, third paragraph of the Introduction Section, the follow- Should read:
ing sentence,
“In efforts to block pro-inﬂammatory responses, we recently
showed that tofacitinib, a Janus kinase (JAK) inhibitor that was
FDA-approved in 2012 for treating rheumatoid arthritis and ulcera-
tive colitis (Traynor, 2012; Sandborn et al., 2012), blocked immune
containment and promoted bacterial replication during chronic TB
in the mouse paucibacillary model in the absence of anti-TB drugs
(Maiga et al., 2012)”.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.014.
⁎ Corresponding author at: Center for Tuberculosis Research, Johns Hopkins University
School of Medicine, 1550 Orleans St., Room 103, Baltimore, MD 21231, USA.
E-mail address: wbishai1@jhmi.edu (W.R. Bishai).
1 Current address: National Institute of Allergic and Infectious Diseases, DIR/LPD,
Bethesda, Maryland, USA.
http://dx.doi.org/10.1016/j.ebiom.2015.10.019
2352-3964/© 2015 The Authors. Published by Elsevier B.V. All rights reserved.“In efforts to block pro-inﬂammatory responses,we recently showed
that tofacitinib, a Janus kinase (JAK) inhibitor thatwas FDA-approved in
2012 for treating rheumatoid arthritis (Traynor, 2012), and shown to in-
duce clinical response and remission in patients with ulcerative colitis
(Sandborn et al., 2012), blocked immune containment and promoted
bacterial replication during chronic TB in the mouse paucibacillary
model in the absence of anti-TB drugs (Maiga et al., 2012)”.
We regret the error.
